Eli Lilly’s (LLY) Weight Loss Pill is Better Than Novo’s, Says Jim Cramer

Pharmaceutical elephantine Eli Lilly and Company (NYSE:LLY) is 1 of Cramer’s favourite stocks successful the space. The shares are up by 16.9% implicit the past twelvemonth and are down by 10.8% year-to-date. The banal closed 9.8% higher connected April 30th arsenic the steadfast reported its first-quarter earnings. The results saw Eli Lilly and Company (NYSE:LLY) station $19.8 cardinal successful gross and $8.55 successful net per stock to bushed expert estimates of $6.66. Cramer has praised the steadfast for aggregate reasons for much than a year. These see a robust manufacturing beingness successful the US and a cause portfolio that expands its beingness successful markets different than value nonaccomplishment drugs. In this appearance, helium discussed Eli Lilly and Company (NYSE:LLY)’s value nonaccomplishment pill and continued to praise the company:

“This is 1 of the top pharma stories, I deliberation it rivals with Keytruda. I’m not kidding. It is amended I deliberation than immoderate of the Abbvie combinations for immunology. You cognize David, the astir important happening that I deliberation is this pill. A batch of radical felt that the pill had a atrocious start. They were utilizing scripts, they said it was lone a 1000 a week, 1,200 a week. It’s a 1000 a time and it’s conscionable starting. That and the pill I deliberation is superior to Novo Nordisk, oregon to the competitors arsenic Ricks said.

“But they’re besides moving connected the pill which is not going to wounded the musculus but conscionable get escaped of the fat. And here’s immoderate numbers that I thought were interesting. 20 cardinal radical instrumentality it and helium thinks that a cardinal radical could instrumentality it. There’s a large a there. . .so I deliberation that the thought that this is down, this is called laughable. That’s is simply a laughable chart, alright, due to the fact that it’s astir to crook up. . .But this is this large Foundayo launch, radical didn’t deliberation Foundayo was doing well, the pill, and I deliberation that 1 of the things that David Ricks said was it’s conscionable fine. Which for David is similar a large deal. . .”

Pixabay/Public domain

Baron Health Care Fund discussed Eli Lilly and Company (NYSE:LLY) successful its Q1 2026 capitalist letter:

“Eli Lilly and Company (NYSE:LLY), a planetary pharmaceutical institution presently champion known for its GLP-1 treatments for diabetes and obesity, detracted from performance. Following a robust 4th fourth of 2025, shares declined aft rival Novo Nordisk launched its oral Wegovy up of Lilly’s oral motorboat successful April 2026. Early medicine trends for oral Wegovy person been strong, prompting capitalist concerns astir imaginable cannibalization of injectable obesity medications and the anticipation of terms cuts from Novo Nordisk igniting a terms war. Novo Nordisk presently offers introductory cash-pay rates connected the starting doses ($149 for oral, $199 for injectable), but patients tin lone entree these promotional prices for 2 months, the discounts use lone to debased starting doses that bash not thrust meaningful value loss, and astir patients yet titrate to higher-priced attraction doses. Longer term, we proceed to presumption Lilly’s Mounjaro and Zepbound, on with its oral GLP-1 orforglipron, arsenic best-in-class attraction options for diabetic and obese patients. We expect GLP 1 therapies to go the modular of attraction and to correspond a $150-billion-plus marketplace opportunity.”